Search results
Results from the WOW.Com Content Network
Dapagliflozin was approved for medical use in the United States in January 2014. [66] [36] In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. [11]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Three drugs have been accepted by the Food and Drug Administration (FDA) in the United States; dapagliflozin, canagliflozin and empagliflozin. Canagliflozin was the first SGLT-2 inhibitor that was approved by the FDA, being accepted in March 2013. Dapagliflozin and empagliflozin were accepted in 2014.
Recently, two pharmaceutical giants received FDA approval for a new treatment for type 2 diabetes. Farxiga (dapagliflozin) is a "sodium-glucose co-transporter 2 inhibitor", or SGLT2 inhibitor for ...
U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes WILMINGTON, Del. & PRINCETON, N.J.-- ...
The FDA has also approved Ozempic to prevent major cardiovascular events like heart attack or stroke in those with type 2 ... This includes canagliflozin (Invokana®) and dapagliflozin (Farxiga®).
To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin ...
Forxiga ™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...